- Conditions
- Langerhans Cell Histiocytosis
- Interventions
- Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin
- Drug · Procedure · Biological
- Lead sponsor
- North American Consortium for Histiocytosis
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia, CLL (Chronic Lymphocytic Leukemia), Chronic Myeloid Leukemia (CML), MDS (Myelodysplastic Syndrome), Non-Hodgkin Lymphomas, Hodgkins Lymphoma, Cutaneous T Cell Lymphomas (CTCL)
- Interventions
- Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC), Post-transplant treatment
- Other
- Lead sponsor
- Ossium Health, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 9
- States / cities
- Duarte, California • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
- Interventions
- Bioelectric Impedance Analysis, Biospecimen Collection, Cardiopulmonary Exercise Testing, Echocardiography, Physical Performance Testing, Pulmonary Function Test, Questionnaire Administration, Ultrasound
- Procedure · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan
- Drug · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 2 Months and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2038
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma, Myeloma
- Interventions
- Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate Mofetil (MMF), Hematopoietic Stem Cell Transplant (HSCT)
- Radiation · Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Systemic Sclerosis
- Interventions
- RIC alloBMT w PTCy in refractory SSc
- Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma
- Interventions
- Fludarabine, Melphalan, Total Body Irradiation
- Drug · Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Interventions
- Fludarabine Phosphate, Tacrolimus, Thiotepa, Total-Body Irradiation (TBI), Magnetic Affinity Cell Sorting, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation
- Drug · Radiation · Other + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 14 Years to 55 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Seattle, Washington
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Hematopoietic Cell Transplantation Recipient
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide, Goat Milk, Laboratory Biomarker Analysis, Palifermin, Sirolimus, Tacrolimus, Total-Body Irradiation
- Procedure · Drug · Other + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 12 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Leukemia, Lymphoma, Low-Grade, Lymphoma, Non-Hodgkin's, Multiple Myeloma, Myelodysplastic Syndromes
- Interventions
- Reduced intensity conditioning, Prophylactic donor leukocyte infusions
- Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Reduced Intensity Conditioning, Busulfan and Fludarabine
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- High Risk Hematologic Malignancies
- Interventions
- stem cell transplant, Stem cell transplant
- Biological · Procedure
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hematological Malignancies
- Interventions
- Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Fludarabine, Busulfan, Hematopoietic stem cell transplantation
- Radiation · Drug · Genetic
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
- Interventions
- Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 1 Year and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 39
- States / cities
- Duarte, California • San Francisco, California • Stanford, California + 28 more
- Conditions
- MPS-IH (Hurler Syndrome)
- Interventions
- Experimental: OTL-203, Active Comparator: Allo-HSCT
- Genetic
- Lead sponsor
- Orchard Therapeutics
- Industry
- Eligibility
- 28 Days to 30 Months
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Interventions
- Conditioning and Stem cell infusion
- Combination Product
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Disease
- Interventions
- Fludarabine Phosphate, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil, Therapeutic Allogeneic Lymphocytes, Laboratory Biomarker Analysis
- Drug · Radiation · Procedure + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 2 more
- Conditions
- Lymphoma
- Interventions
- lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells, carmustine, cyclophosphamide, etoposide, autologous hematopoietic stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- fludarabine phosphate, cyclophosphamide, Rituxan (rituximab), filgrastim, methylprednisolone, immunologic technique, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, Diphenhydramine, Mesna
- Drug · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Granulomatous Disease (CGD)
- Interventions
- Busulfan, Tocilizumab, Eltrombopag, Sirolimus, pCCLChimGp91lentiviral vector containing the human gp91 phox (CYBB) gene
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hematologic Malignancies
- Interventions
- Biological: ProHema-CB
- Biological
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Duarte, California • Boston, Massachusetts
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML), Multiple Myeloma (MM), Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell), Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
- Interventions
- milatuzumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Blood Disorders
- Interventions
- Patient-Centered Medical Home (PCMH), Standard Care
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina